Adagrasib M68 metabolite

SL-10117

Adagrasib M68 metabolite, >98%

CAS No. : [2326525-51-1]

IUPAC Name : 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methyl-5-oxopyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
10MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
25MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
50MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026
100MG	Request A Quote		In Stock	Estimated to ship on 20 September 2026

Applications : This is a metabolite of Adagrasib, which is a potent, orally available, mutation-selective covalent inhibitor targeting KRAS G12C, demonstrating potential antineoplastic properties. Adagrasib forms a covalent bond with the cysteine at position 12 of KRAS G12C, thereby stabilizing the protein in its inactive GDP-bound conformation and effectively inhibiting KRAS-dependent signal transduction.

References : Christensen J. G. et al.: Cancer Discov., pii: CD-19-1167, 2019; Kyriakos P. P. et al.: Journal of Clinical Oncology 37, 15_suppl, TPS3161-TPS3161, 2019; Fell J. B. et al.: J. Med. Chem., 63(13), 6679-6693, 2020; Awad M. M. et al.: N Engl J. Med. 384(25), 2382-2393, 2021.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.